Tailored prediabetes works

Preliminary findings were delivered as a moderated poster (MPTU11) by Mary Rooney, PhD, MPH, of the Johns Hopkins Bloomberg School of Public Health at the American Heart Association EPI|Lifestyle Scientific Sessions in Boston, March 17–20, 2026. (newsroom.heart.org) The analysis pooled 662 adults aged 18–40 from three U.S. cohorts — the Hispanic Community Health Study/Study of Latinos, the CARDIA study and the Framingham Heart Study Third Generation — with participants followed for an average of seven years. (newsroom.heart.org) Investigators estimated an overall five‑year risk of progression from prediabetes to Type 2 diabetes of 7.5% in the pooled sample. (news-medical.net) The team reported subgroup risks of 10.9% for people meeting GLP‑1 receptor‑agonist treatment eligibility, 15.1% for those with fasting glucose 110–125 mg/dL, and 24.8% for participants who had both higher fasting glucose and GLP‑1RA eligibility. (news-medical.net) (medicalxpress.com) The analysis applied FDA‑style GLP‑1RA eligibility thresholds — BMI ≥30 kg/m2 or BMI ≥27 kg/m2 plus at least one related condition such as hypertension or high cholesterol — while noting that GLP‑1RA drugs are not FDA‑approved for diabetes prevention in people with prediabetes. (medicalxpress.com) Complementary research this year has produced individualized 3‑year diabetes risk prediction models that incorporate estimated effects of preventive interventions (metformin and intensive lifestyle) using the Diabetes Prevention Program trial as a derivation cohort, illustrating an analytic pathway for tailoring prevention to individual predicted benefit. (diabetesjournals.org) (repository.niddk.nih.gov)